An Orally Active Cannabis Extract with High Content in Cannabidiol attenuates Chemically-induced Intestinal Inflammation and Hypermotility in the Mouse

Article English OPEN
Pagano, Ester ; Capasso, Raffaele ; Piscitelli, Fabiana ; Romano, Barbara ; Parisi, Olga A. ; Finizio, Stefania ; Lauritano, Anna ; Marzo, Vincenzo Di ; Izzo, Angelo A. ; Borrelli, Francesca (2016)
  • Publisher: Frontiers Media S.A.
  • Journal: Frontiers in Pharmacology, volume 7 (issn: 1663-9812, eissn: 1663-9812)
  • Related identifiers: doi: 10.3389/fphar.2016.00341, pmc: PMC5047908
  • Subject: Cannabis sativa | cannabidiol | colitis | Pharmacology | intestinal motility | cannabinoids | Original Research | inflammatory bowel disease
    mesheuropmc: digestive system | surgical procedures, operative | digestive system diseases

Anecdotal and scientific evidence suggests that Cannabis use may be beneficial in inflammatory bowel disease (IBD) patients. Here, we have investigated the effect of a standardized Cannabis sativa extract with high content of cannabidiol (CBD), here named CBD BDS for “CBD botanical drug substance,” on mucosal inflammation and hypermotility in mouse models of intestinal inflammation. Colitis was induced in mice by intracolonic administration of dinitrobenzenesulfonic acid (DNBS). Motility was evaluated in the experimental model of intestinal hypermotility induced by irritant croton oil. CBD BDS or pure CBD were given - either intraperitoneally or by oral gavage – after the inflammatory insult (curative protocol). The amounts of CBD in the colon, brain, and liver after the oral treatments were measured by high-performance liquid chromatography coupled to ion trap-time of flight mass spectrometry. CBD BDS, both when given intraperitoneally and by oral gavage, decreased the extent of the damage (as revealed by the decrease in the colon weight/length ratio and myeloperoxidase activity) in the DNBS model of colitis. It also reduced intestinal hypermotility (at doses lower than those required to affect transit in healthy mice) in the croton oil model of intestinal hypermotility. Under the same experimental conditions, pure CBD did not ameliorate colitis while it normalized croton oil-induced hypermotility when given intraperitoneally (in a dose-related fashion) or orally (only at one dose). In conclusion, CBD BDS, given after the inflammatory insult, attenuates injury and motility in intestinal models of inflammation. These findings sustain the rationale of combining CBD with other minor Cannabis constituents and support the clinical development of CBD BDS for IBD treatment.
  • References (58)
    58 references, page 1 of 6

    Ananthakrishnan A. N. (2015). Epidemiology and risk factors for IBD. Nat. Rev. Gastroenterol. Hepatol. 12 205–217. 10.1038/nrgastro.2015.34

    Aviello G. Romano B. Izzo A. A. (2008). Cannabinoids and gastrointestinal motility: animal and hu man studies. Eur. Rev. Med. Pharmacol. Sci. 12(Suppl. 1), 81–89.

    Borrelli F. Aviello G. Romano B. Orlando P. Capasso R. Maiello F. (2009). Cannabidiol, a safe and non-psychotropic ingredient of the marijuana plant Cannabis sativa, is protective in a murine model of colitis. J. Mol. Med. 87 1111–1121. 10.1007/s00109-009-0512-x

    Borrelli F. Fasolino I. Romano B. Capasso R. Maiello F. Coppola D. (2013). Beneficial effect of the non-psychotropic plant cannabinoid cannabigerol on experimental inflammatory bowel disease. Biochem. Pharmacol. 85 1306–1316. 10.1016/j.bcp.2013.01.017

    Borrelli F. Romano B. Petrosino S. Pagano E. Capasso R. Coppola D. (2015). Palmitoylethanolamide, a naturally occurring lipid, is an orally effective intestinal anti-inflammatory agent. Br. J. Pharmacol. 172 142–158. 10.1111/bph.12907

    Brierley S. M. Linden D. R. (2014). Neuroplasticity and dysfunction after gastrointestinal inflammation. Nat. Rev. Gastroenterol. Hepatol. 11 611–627. 10.1038/nrgastro.2014.103

    Brodie J. S. Di Marzo V. Guy G. W. (2015). Polypharmacology shakes hands with complex aetiopathology. Trends Pharmacol. Sci. 36 802–821. 10.1016/j.tips.2015.08.010

    Burstein S. (2015). Cannabidiol (CBD) and its analogs: a review of their effects on inflammation. Bioorg. Med. Chem. 23 1377–1385. 10.1016/j.bmc.2015.01.059

    Campos A. C. Moreira F. A. Gomes F. V. Del Bel E. A. Guimarães F. S. (2012). Multiple mechanisms involved in the large-spectrum therapeutic potential of cannabidiol in psychiatric disorders. Philos. Trans. R. Soc. Lond. B Biol. Sci. 367 3364–3378. 10.1098/rstb.2011.0389

    Capasso R. Borrelli F. Aviello G. Romano B. Scalisi C. Capasso F. (2008). Cannabidiol, extracted from Cannabis sativa, selectively inhibits inflammatory hypermotility in mice. Br. J. Phar macol. 154 1001–1008. 10.1038/bjp.2008.177

  • Metrics
    No metrics available
Share - Bookmark